menu
    • menu
    [{"orgOrder":0,"company":"Juno Pharmaceuticals Pty Ltd","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"AUSTRALIA","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Eptifibatide","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Juno Pharmaceuticals Pty Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Juno Pharmaceuticals Pty Ltd \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Juno Pharmaceuticals Pty Ltd \/ Not Applicable"},{"orgOrder":0,"company":"Avenacy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Eptifibatide","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avenacy \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Avenacy \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Eptifibatide

    Menu

    Eptifibatide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Avenacy

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            Avenacy

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eptifibatide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Avenacy Announces Launch of Eptifibatide for Injection in the U.S. Market

                            Details : Integrilin-Generic (eptifibatide) is a USFDA approved platelet aggregation inhibitor, which is indicated for the treatment of patients with acute coronary syndrome.

                            Product Name : Integrilin-Generic

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 29, 2024

                            Lead Product(s) : Eptifibatide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Juno Pharmaceuticals Pty Ltd

                            Australia arrow
                            The Generic Rx Session
                            Not Confirmed

                            Juno Pharmaceuticals Pty Ltd

                            Australia arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eptifibatide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Juno Pharmaceuticals Receives Approval to Import Eptifibatide as Canadian Hospitals Continue to Grapple with S...

                            Details : Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Not Applicable

                            March 30, 2023

                            Lead Product(s) : Eptifibatide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth